Day 1 :
Keynote Forum
Yasser Mohamed Lotfy Zaghloul
Sheikh Khalifa Medical City, UAE
Keynote: The role of short-acting drugs in modern anaesthesia
Time : 09:45-10:30
Biography:
Yasser Zaghloul MBBCH, Ms Sc, MD PhD, FCARCSI (Ireland) - The Current position is Consultant of Anesthesia; Sheikh Khalifa Medical City – Abu Dhabi –UAE. The Director of Abu Dhabi Anesthesia Club and Anesthesia Refresher Course and also Lecturer and instructor in the following international courses: FCCS, PFCCS, ENLS, Airway Management, Critical Care Nephrology and mechanical ventilation courses. The Previous work is Consultant of Anesthesia & ICU in Ireland. Did the Graduation in 1986 from Faculty of Medicine, Alexandria University – Egypt. He has been trained in anesthesia and critical care medicine in both Egypt and Ireland. He has extensive experience and interest in neuro-anaethesia & neurocritical care, neonatal & pediatric anesthesia and perioperative medicine. He have delivered more than 160 lectures in international anesthesia, pain & ICU conferences
Abstract:
- Food and Nutritional Toxicology |Immunopharmacology and Immunotoxicology |Pharmacokinetics and Pharmacodynamics | Pharmacotherapeutics and Drug Toxicity |Drug Discovery, Drug Development, and Posology | Psychopharmacology and Pharmacoepidemiology
Chair
Yuying Gao
Certara China, USA
Co-Chair
Noon Abubakr Abdelrahman Kamil
Fatima College of Health Sciences, UAE
Session Introduction
Yuying Gao
Certara China, USA
Title: Value of pharmacometrics analyses in drug development
Time : 10:30-11:00
Biography:
Yuying Gao is a trained anesthesiologist and clinical pharmacologist with more than 100 published books, manuscripts and abstracts and 20 years of modeling and simulation experience in optimizing treatment and bridging strategies, trial designs and drug development decision-making. In 2006, she joined Certara (formerly Quantitative Solutions) in its infancy and served as director of the Drug Development Consulting Services, general manager of Asia-Pacific region, and vice president, most recently as President and CEO of Certara Strategic Consulting China. Prior to joining us in 2006, she was senior scientist at the Pharsight Corporation (now Certara) from 1999 to 2006. During her career in both medical and consulting services, she has established herself as a thought expert in the field of anesthesiology and pharmacometrics. She has worked with more than 60 pharmaceutical companies and modeled more than 150 compounds in clinical development. Her work covers all therapeutic areas with recent focus on cardiovascular disease, oncology and neuroscience
Abstract:
The process of drug development is extremely time consuming and costly. It takes approximately 10-12 years and costs hundreds of millions or billions dollars. Pharmacometrics is the scientific discipline that uses mathematical models based on biology, pharmacology, physiology, and disease for quantifying the interactions between drugs and patients. Its purpose is to reduce cost and shorten development time by optimizing the clinical assessment of efficacy and safety. This presentation highlights the value of pharmacometric analyses in drug development through selected examples.
Mohamad Samer Mouksassi
Certara Consulting Services, Canada
Title: PK/PD modeling and trial simulation for everyone
Time : 11:30-12:00
Biography:
Mohamad Samer Mouksassi is an established pharmacometrician providing solutions for optimizing drug development and health care problems. He holds a clinical degree PharmD (Lebanese University), and postgraduate degrees in Biostatistics, Epidemiology and Pharmacokinetics Modeling and Simulation from University of Montreal, PQ, Canada. During his industry experience Samer’s team successfully obtained several regulatory approvals for several therapeutic indications namely in pediatrics and rare diseases. More recently, Samer was the key analyst that led the efforts to successfully qualify an imaging biomarker for polycystic kidney disease. He continues to specialize in bringing therapeutic options for neglected diseases and vulnerable populations.
Abstract:
Nowadays it is rare to see any FDA submission package without a Pharmacokinetics/Pharmacodynamics modeling component where some clinical trials were designed based on simulation. The current workflow is that an expert modeler provide model outputs and simulation about scenarios that he thinks are important to emulate future trials and decisions. Then, the decision maker might then ask for new more relevant scenarios to the current situation. This decision process is iterative where one simulated scenario might warrant another question/scenario that need to be tested until we reach a satisfactory decision. As such this involves sveral cycles of back and forth. All this results in bottlenecks cycles where the decision maker is waiting for simualtion results and where simulation scientists are waiting for decision maker to give them more scenarios to test. Why is this ? The simulation workflow is so complicated that only the person who built the underlying models and simulation scenarios can get useful answers. However, recent technological advances has enabled simulation scientists to build specialized user interfaces that enable decision makers to be part of the design team and ask questions and get answers on the fly. Today this is possible using web based responsive user interface A successful simulation exercice involve a mathematical modeler (e.g.pharmacometrician), a clinical trial expert, a therapeutic area expert (or a clinician) a computational/web developer expert and the clinical development decision maker. An example of the development of such an app for Tuberculosis will be demoed.
Azrifitria Amiruddin
Syarif Hidayatullah State Islamic University, Indonesia
Title: Potential nutritional and in-vitro inhibitory effects on a- glucosidase of sea hare (Dolabella auricularia
Time : 12:00-12:30
Biography:
Azrifitria has completed her PhD at the Indonesia University School of Medicine. She is the Head of Pharmacy Department at Syarif Hidayatullah State slamic University Jakarta, Indonesia. She has published several papers in reputed journals and get some course at pharmacy field at Tokushima Bunry Japan.
Abstract:
Dolabella auricularia, also known as sea hare, is a marine gastropod that it found in the waters of Indo – Pacific. The aims of this research were to explore the potential of nutritional content of the species and in vitro anti-diabetic activity of sea hare extract. The composition of fatty acid was measured by gas chromatography, amino acids were measured by high performance liquid chromatography and mineral was measured by atomic absorption spectrophotometer. In vitro anti-diabetic activity of the sea hare extracts was evaluated by measuring their inhibitory effect on alpha-glucosidase level. The sea hare contained nine essential amino acids and six non-essential amino acids. Total saturated fatty acids was at 5.33% (g /100g), MUFA at 2.11% (g/ 100g), PUFA at 4.1% (g/100g). Calcium was at 68100 mg/kg, potassium at 10000 mg/kg, sodium at 8200 mg/kg, and carbohydrate at 1.52%. Sea hare ethyl acetate extract has in vitro anti-diabetic activity better than methanolic extract. The ethyl acetate extracts inhibited alpha-glocosidase activity in vitro, in a concentration dependent manner (IC50=25.76 mg/mL). The present study confirms that sea hare had a rich source of nutritional and their inhibitory effects on alpha-glucosidase.
Alaa Alqahtani
Umm Al- Qura University, Saudi Arabia
Title: Novel bufadienolide glycoside and a homoisoflavonoid from Rhodocodon campanulatus (Asparagaceae)
Time : 12:30-13:00
Biography:
Alaa Alqahtani is an Assistant Professor in Pharmaceutical Chemistry Department at Umm Al- Qura University. She has completed her Graduation from Umm AlQura Universityand Master’s in Chemistry with Biological Chemistry from University of Hull, UK. She completed her PhD from Surrey University, UK in the field of Natural Products Chemistry (Pharmaceutical Chemistry). Her research focuses on the discovery of novel drugs from traditional medicinal plants, marines and their determination of their absolute stereo structures using electronic circular dichroism. Her areas of expertise includes, isolation, identification and quantification of compounds from natural sources, synthesis of bioactive molecules and examine the possible biological activities of these compounds.
Abstract:
Rhodocodon campanulatus is a member of the bulbous Urgineeae tribe of the Scilloideae subfamily of the expanded Asparagaceae family (formerly Hyacinthaceae). Plants of the Urgineeae tribe are used as traditional remedies for the treatment of several ailments, such as infections, rheumatism, inflammation and disorders associated with the central nervous system. The Urgineeae tribe is distributed from South Africa to the Mediterranean, Saudi Arabia, India and Myanmar. The chemical constituents of plants of the Rhodocodon genus are not documented and hence the plant was investigated for chemo-taxonomical reasons. In this study we report the isolation of a novel bufadienolide glycoside and a known homo-isoflavonoid from the ethanol extract of the bulbs of Rhodocodon campanulatus. The major compounds were novel bufadienolide glycoside, 1, 3β-(O-β-D-glucopyranoside)- 14β-hydroxybufa-20,22-dienolid-19-al, and the known homo isoflavonoid, 2, 5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl) chroman-4-one, previously isolated from the South African Scilla kraussi. The structures of 1 and (2, 2a-b) (figure 1) were determined by the analysis of their NMR and MS spectra. The absolute configuration at C-3 for 2 was determined in this study as S on the basis of its electronic circular dichroism study. A positive Cotton effect at 290 was in agreement to those reported for homo isoflavonoid with H-3 in β position. Compound 1 was screened against NCI60 cancer cell lines and did not show any significant growth inhibition. Compound 2-2a-b was tested for anti-angiogenic inhibition ability. Compound 2b was found to be effective against the angiogenesis of human retinal micro vascular endothelial cells (HRECs) with GI50 values of 128 μM. Recent Publications 1. Schwikkard Sianne, Alqahtani Alaa, Knirsch Walter, Wertschnig Wolfgang, Jaksevicius Andrius, Opara Elizabeth, Langat Moses K and Mulholland Dulcie (2017) Phytochemical investigations of three Rhodocodon (Hyacinthaceae sensu APG II) species. J. Nat. Prod; 80: 30-37.
Safinaz Ibrahim Khalil Ahmed
University of Medical Sciences and Technology, Sudan
Title: A study of CYP2C19*2, *3 and *7 in different Sudanese ethnic groups and their response to Omeprazole based triple therapy in Khartoum, Sudan 2016-2017
Time : 14:00-14:30
Biography:
Safinaz Ibrahim Khalil has her expertise in evaluation and passion in improving the health and wellbeing. Her open and contextual evaluation model based on responsive constructivists creates new pathways for improving healthcare. She has built this model after years of experience in research, evaluation, teaching and administration both in hospital and education institutions.
Abstract:
Background: Pharmaco-genetics is an important branch of pharmacology and should be applied to assist the clinical usage of medicines which has a strong relation with enzyme activity of certain genes and alleles known through the literature. CYP2C19 is known to affect the activity of omeprazole and this will result in different responses to treatment. The commonest alleles through the literature are CYP2C19*2 and CYP2C19*3 which vary according to different ethnicity of different populations. Methodology: A purposeful convenient sampling; in which patients with peptic ulcer disease and treated with omeprazole were reviewed and the PCR is used to differentiate the CYP2C19 different alleles in patients presenting from February 2016 to January 2017. Results: In the present study we investigated the distribution of three common gene variants affecting the omeprazole treatment of peptic ulcer disease and H. pylori eradication namely to CYP2C19*2, *3 and *7. The CYP2C19*2 mutation was found among all seven ethnic groups of Sudan, Arabs mostly 17 (139) followed by Darfurians 9 (139), Beja 6 (139) and Nilotes 6 (139), Nuba 5 (139) then Nubians 3 (139) and Fulani 1 (139), p=0.048 which is significant. Regarding CYP2C19*3 mutation of this allele is found in certain ethnic groups Arabs 6 (139), Nubians 6 (139) and Nuba 2 (139), p=0.043 significant. There is no mutation found among different Sudanese ethnic groups in CYP2C19*7. Arabs are normal homozygotes 6 (139) and Darfurians 1 (139). Nuba 1 (139) was found to be heterozygotes in this allele p=0.038 significant. Treatment of H. pylori with omeprazole-based triple therapy was used in 110 (139) and no significant correlation found with the different ethnic groups of Sudan. Conclusion: These data indicate that Sudanese seven ethnic groups showed activity of CYP2C19*2, CYP2C19*3 were they took omeprazole based triple treatment and some of them showed activity to CYP2C19*7.
Zilhadia Anwar Hasibuan
Syarif Hidayatullah State Islamic University, Indonesia
Title: Physicochemical and pharmaceutical properties of gelatin extracted from goat skin: The new excipient in pharmaceutical and food dossage form
Time : 14:30-15:00
Biography:
Zilhadia Anwar Hasibuan has completed his PhD from Faculty of Pharmacy University of Indonesia. She is a Lecturer and the Director of Pharmacy Medicine Laboratory Syarif Hidayatullah State Islamic University. She has published several papers in reputed journals and as presenter in several international conferences.
Abstract:
Generally the gelatin used in pharmaceutical and food dosage form was obtained from bovine and porcine. This research explored the new alternative source of gelatin, namely goat skin. Goat skin was soaked in hydrochlorid acid and then gelatin was extracted using warm water. Their physicochemical and pharmaceutical properties were investigated. A yield of 12.74±0.87 g/100 g skin sample on the basis of wet weight was obtained. Organoleptic of goat gelatin powder is a vitreous, brittle solid faintly yellow in color, nearly tasteless and odorless. The result of physicochemical properties exhibited the following: sulfide content of 7.18±0.68 ppm, lead, zinc and copper were not detected. % transmittance of goat gelatin solution revealed clarity value was 56.9±0.95. pH, moisture and ash content were 5.11±0.9, 9.23±0.9 and 0.18±0.16, respectively. The results of pharmaceutical properties including emulsion activity index, foaming properties, gel strength and viscosity were 77.23±23, 118.87±0.12, 307.67±2.64 and 25.5±1.83, respectively. The microbial assay showed microbes were not detected. All of these physicochemical and pharmaceutical properties of goat skin gelatin indicated that it meets the defined requirements of a good gelatin and could use as alternative material in pharmaceutical and food dosage form.
Rajan Radhakrishnan
Mohammed Bin Rashid University of Medicine and Health Sciences, UAE
Title: Common reasons for rejection of scientific manuscripts in pharmacology
Time : 15:00-15:30
Biography:
Rajan Radhakrishnan is a Pharmacologist and a US-registered pharmacist, currently serving as a professor of pharmacology at the Mohammed Bin Rashid University College of Medicine in Dubai. He has more than 20 years of combined experience in teaching, research, and academic administration. He received his BPharm degree from the University of Kerala, India; MSc in pharmacology from the University of Strathclyde, UK; and PhD in pharmacology from the National University of Singapore (NUS). He did his postdoctoral fellowship in pain neurobiology at the University of Iowa, USA. He has taught pharmacology to pharmacy, medical and dental students in different universities in Malaysia, USA and UAE. He has also served as the Academic Affairs Dean at the Schools of Pharmacy in Roseman University and University of Charleston in the USA. Dr. Radhakrishnan is an active member of the American Association of Colleges of Pharmacy (AACP), American Pain Society (APS), and Society for Neuroscience (SFN). He has published 40 peer-reviewed research articles, 5 book chapters and several abstracts. He is one of the editors of Phytotherapy Research (Wiley), Section Editor of Inflammopharmacology (Springer) and Editorial Board Member of Journal of Pain (Elsevier). He is also in the reviewer panel of more than 15 International scientific journals. His current research interests are pain neurobiology, herbal medicine, and scholarship of teaching and learning (SoTL ).
Abstract:
A significant number of manuscripts submitted to international scientific journals are from China, India, Pakistan and other developing countries. However, the acceptance rates of manuscripts from these countries are much lower than the average acceptance rates of manuscripts in these journals. Major reasons for rejection are: (1) Flawed study design, (2) inappropriate data analysis methods, (3) lack of study justification, (4) lack of novelty/data duplication, (5) lack of chemical fingerprinting/ standardization of extracts, (6) study conclusions without supporting data and (7) poor writing style, language, formatting. This presentation will focus on the details of common reasons for rejection and suggestions for improvement.
Nurmeilis Nurdjaman Pujianto
Syarif Hidayatullah State Islamic University, Indonesia
Title: In-vivo anti-inflammatory activity of ethanol extract of the parijoto fruit (Medinilla speciosa Blume)
Time : 15:30-16:00
Biography:
Nurmeilis Nurdjaman Pujianto has completed her PhD from Faculty of Pharmacy University of Indonesia in 2016. She is a Lecturer in Pharmacology since 2005 at Pharmacy Department Faculty of Medicine and Health Sciences Syarif Hidayatullah State Islamic University (UIN) Jakarta, Indonesia. She is currently (since 2016) the Head of Pharmacy Department. She has published several paper in both international and national journal also presentation as oral presenter in international conference.
Abstract:
Parijoto (Medinilla speciosa Blume) is traditionally plant that used on diarrheal diseases, inflammation and cancer sores and potentially as anti-hyperlipidemia and anti-bacterial that have been tested in vivo and in vitro. Based on research, parijoto fruit contains secondary metabolites such as flavonoids, tannins, saponins and glycosides. The purpose of this study was to determine the anti-inflammatory activity of the ethanol extract parijoto by using Carrageenan-Induced Paw Edema method. Sprague Dawley rats were divided into five groups: Negative control (Na CMC 0.5% b/v), positive control (Diclofenac sodium 5.14 mg/kg BW), ethanol extract parijoto fruit in various doses of 100, 200 and 400 mg/kg body weight. The test substances are given orally before induction with 0.2 mL carrageenan 1%. Measuring of the volume of rat's paw is conducted every hour for five hours after carrageenan induction by using plethysmometer. The results showed that rats which were given ethanol extract of 100, 200 and 400 mg/kg BW have significantly different percentage of edema compared to the negative control group (p≤0.05). The percentage of edema inhibitions within the subjects group with doses of 100, 200 and 400 mg/kg BW are 74.58%, 72.88%, dan 50.85%, respectively. This result suggested that extract ethanol parijoto fruits are able to inhibit edema of rat’s paw which is indicated that this extract has a potency to be developed as the anti-inflammatory agent.